Title: The Seeming Anomaly of Hydrogen Peroxide Source: Townsend Letter for Doctors & Patients Date: June 1996 You might think one of the bad guys couldn't be useful in therapy. The explanation is found in the extremely low concentration used - typically, 0.04%. Some competent researchers fear that active oxygen creates free radicals in the body, and so might promote arterial damage and cancer, acccelerate aging and do other mischief. But when active oxygen as ozone (O3) or hydrogen peroxide (H2O2) is used at the right low concentration, the highly reactive oxygen free radicals are beneficial rather than harmful. Why? Negative and positive electrical charges attract eaach other. The body is negatively charged; microbes, viruses and toxins are positively charged. Active oxygen is negatively charged; and so if there's enough negative oxygen to neutralize the positive invaders, all is well. If not, then the positively charged bad guys stick to the negatively charged body instead of being washed out. And so these oxygen free radicals scavenge dangerous free radicals. Oxygen therapies are legal everywhere except the U.S. In Europe, the therapies are being used by 5,000 individual physicians, although doctors in major hospitals and medical centers ridicule them. Medical schools teach what pharmaceutical companies research and what government health agencies grant research money for; and what both of these groups study is what is patentable and so makes money. To "justify" their policy, in the Federal Register in 1974 the FDA cited research showing that atmospheric ozone irritates the lungs of sick people, and so declared it a toxic, illegal gas without medical application. Of course, no one uses ozone that way, and the FDA ignores the many successful therapies. However, thanks to political pressure from Senator Tom Harkin, Phase I trials for toxicity have been completed at University of Naples, Italy. HIV and hepatitis B infected subjects were treated for three months using Medizone Corporation's patented technology. Infected blood was exposed to an ozone/oxygen mixture diffused through an extacorporeal blood-carrying device, then restored to the patient; matched control groups were treated with a placebo. As in any double blind test, neither the subjects nor the doctors running the test know who is getting what - until the therapy begins to produce better health - or, in drug tests, adverse side effects. Participants are being tracked for nine months. If this finds the therapy safe, phase 2 tests for effectiveness will follow in Italy and perhaps in the U.S.